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Background: Melanoma is notorious for its propensity to metastasize, which makes treatment extremely difficult.
Receptor tyrosine kinase c-Met is activated in human melanoma and is involved in melanoma progression and
metastasis. Hepatocyte growth factor (HGF)-mediated activation of c-Met signaling has been suggested as a therapeutic
target for melanoma metastasis. Quercetin is a dietary flavonoid that exerts anti-metastatic effect in various types of
cancer including melanoma. In a previous report, we demonstrated that quercetin inhibited melanoma cell migration
and invasion in vitro, and prevented melanoma cell lung metastasis in vivo. In this study, we sought to determine the
involvement of HGF/c-Met signaling in the anti-metastatic action of quercetin in melanoma.
Methods: Transwell chamber assay was conducted to determine the cell migratory and invasive abilities. Western
blotting was performed to determine the expression levels and activities of c-Met and its downstream molecules. And
immunoblotting was performed in BS3 cross-linked cells to examine the homo-dimerization of c-Met. Quantitative
real-time PCR analysis was carried out to evaluate the mRNA expression level of HGF. Transient transfection was used to
overexpress PAK or FAK in cell models. Student’s t-test was used in analyzing differences between two groups.
Results: Quercetin dose-dependently suppressed HGF-stimulated melanoma cell migration and invasion. Further study
indicated that quercetin inhibited c-Met phosphorylation, reduced c-Met homo-dimerization and decreased c-Met
protein expression. The effect of quercetin on c-Met expression was associated with a reduced expression of fatty
acid synthase. In addition, quercetin suppressed the phosphorylation of c-Met downstream molecules including
Gab1 (GRB2-associated-binding protein 1), FAK (Focal Adhesion Kinase) and PAK (p21-activated kinases). More
importantly, overexpression of FAK or PAK significantly reduced the inhibitory effect of quercetin on the migration of
the melanoma cells.
Conclusions: Our findings suggest that suppression of the HGF/c-Met signaling pathway contributes to the
anti-metastatic action of quercetin in melanoma.
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The incidence and mortality rates of melanoma have in-
creased world-wide in the last 30 years [1]. Melanoma is
notorious for its propensity to metastasize. Early stage
melanoma is readily treatable, but advanced metastatic
melanoma becomes resistant to treatment. It is reported
that the long-term survival rate for patients with meta-
static melanoma is only 5% [2]. Currently available che-
motherapeutic approaches for melanoma often carry* Correspondence: zlyu@hkbu.edu.hk
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unless otherwise stated.tolerance, low response rate [3] and high toxicity [4,5].
New targeted therapies with high response rate and low
toxicity are urgently needed for managing malignant
melanoma.
Recently, the role of receptor tyrosine kinase c-Met in
melanoma pathogenesis has been gaining interest. c-Met
is a cell surface receptor consists of a 50-kDa extracellu-
lar α chain and a 140-kDa membrane-spanning β chain,
and is synthesized from a single-chain 170-kDa precursor
[6]. Binding of HGF (hepatocyte growth factor), the only
known endogenous ligand of c-Met [7], to c-Met leads tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phosphorylated regions of c-Met then act as the multi-
function docking site for adaptor molecules which propa-
gate a signaling cascade through a number of effector
proteins [8]. Dysregulation of c-Met has been found in
many types of cancer, which usually correlated with a poor
prognosis [9]. Interestingly, abnormal activation of c-Met
signaling is implicated in the acquisition of tumorigenic
and metastatic phenotypes in tumors [10,11]. Examina-
tions indicated that c-Met was expressed and activated in
melanoma tissues and cell lines [12]. Studies showed that
overexpression of c-Met was associated with melanoma
growth and metastasis [13,14]. Constitutive activation of
c-Met signaling has been reported to promote melanoma
metastasis in mice [15,16], while inhibition of c-Met sig-
naling with a specific small molecule tyrosine kinase in-
hibitor reduced growth and metastasis of experimental
human melanoma [17,18]. Blockade of c-Met signaling
with the specific small interfering (si) RNA also induced
melanoma cell differentiation and prevented melanoma
metastasis in a mouse model [17,18]. These studies sug-
gest that c-Met is a therapeutic target for melanoma
metastasis.
The dietary flavonoid quercetin (3,3’,4’,5,7-pentahy-
droxyflavone) is a bioactive compound that wildly dis-
tributed in the plant kingdom. It possesses low intrinsic
toxicity and does not have carcinogenic activity in vivo
[19]. Besides, it has a relatively high oral bioavailability
[20]. Quercetin has many biological functions including
anti-melanoma activity [21]. Several studies showed that
quercetin inhibited melanoma growth [22-24] and me-
tastasis [25,26]. Moreover, quercetin also inhibited
HGF-induced c-Met phosphorylation in human medul-
loblastoma cell line DAOY [27], and suppressed HGF-
stimulated migration and invasion in DAOY cells [27]
and human hepatoma HepG2 cells [28].
Our published data [29] demonstrated that quercetin
inhibited melanoma cell migration and invasion in vitro
and prevented melanoma lung metastasis in vivo. Here,
we show that quercetin inhibits HGF/c-Met signaling
manifested by suppressing c-Met phosphorylation, inter-
fering c-Met dimerization, reducing c-Met protein ex-
pression and attenuating the activities of downstream
molecules including Gab1, FAK and PAK, which con-
tributes to the anti-metastatic action of quercetin in
melanoma.
Results
Quercetin suppressed HGF-stimulated melanoma cell
migration and invasion
The effects of quercetin on HGF-stimulated melanoma
cell migration and invasion were determined by the
Transwell chamber assays. As shown in Figure 1A, HGF
significantly enhanced the migratory abilities in melanomaA2058 and A375 cells. After a 24-h stimulation with HGF,
the numbers of A2058 and A375 cells that migrated
through the membranes were 4.3-fold and 1.8-fold more
than that under unstimulated condition, respectively. A
48-h stimulation with HGF also caused a significant in-
crease in cell migration, whereas treatment with quercetin
reduced cell migratory abilities in a dose-dependent man-
ner. In parallel, a Matrigel invasion assay showed that
stimulation with HGF significantly increased the invasive-
ness of melanoma cells at both 24 h- and 48 h-incubation
periods, and this effect was dose-dependently reverted by
quercetin treatments (Figure 1B). Under all these condi-
tions, quercetin did not affect cell proliferation (Additional
file 1: Figure S1). These results indicate that quercetin
dose-dependently inhibits HGF-stimulated melanoma cell
migration and invasion.Quercetin reduced c-Met phosphorylation and
dimerization
It has been reported that activation of the HGF/c-Met
pathway promotes cell invasion, migration and allows
cancer metastasis [9]. Therefore, we examined if quer-
cetin inhibited the HGF/c-Met signaling pathway. Cells
were treated with either the vehicle or quercetin
(60 μM) for 6 h, and then stimulated with or without
HGF (100 ng/ml) for 10 min. Figure 2A showed that un-
stimulated cells had low c-Met phosphorylation level at
the major auto-phosphorylation sites Tyr1234/5, while
stimulation with HGF significantly increased c-Met
phosphorylation. Interestingly, pre-treatment with quer-
cetin reduced the phosphorylation of c-Met in the HGF-
stimulated cells. To eliminate the influence of serum
growth factors, cells were grown in serum-free medium
overnight and then treated with either the vehicle or
quercetin (60 μM) for 6 h before stimulating with
100 ng/ml HGF for 10 min. Data from the Western blot
analysis showed that c-Met hardly phosphorylated in
starved cells and stimulation with HGF remarkably in-
creased c-Met phosphorylation levels at the Tyr1234/5
sites and the multi-substrate docking site Tyr1349,
whereas pre-incubation with quercetin decreased the
phosphorylation levels of c-Met in the HGF-stimulated
cells (Figure 2B). In addition, we observed that total c-
Met expression levels were reduced by quercetin treat-
ment (Figure 2A and B).
Next, we determined if quercetin affected c-Met
dimerization. As shown in Figure 2C, incubation with a
cross linker BS3 increased c-Met dimerization (lane 3
versus 1), while pretreatment with quercetin reduced the
expression level of c-Met dimer (lane 4 versus 3). Be-
sides, stimulation with HGF caused an apparent c-Met
dimerization (lane 5 versus 3), which was also inhibited
by quercetin pre-incubation (lane 6 versus 5).
Figure 1 Quercetin suppressed HGF-stimulated melanoma cell migration and invasion. A2058 and A375 cells were seeded onto the upper
chamber consisting of 8 μm pore-size filters coated without (A) and with (B) Matrigel basement membrane matrix, then treated with indicated
concentration of quercetin for 24 h or 48 h without (−) or with (+) 100 ng/ml HGF in the lower chamber. The relative quantitative determinations
of migrated and invasive cells were calculated with 5 fields counted per experiment. Data were shown as mean ± S.D. from three independent
experiments, ###P < 0.001 compared with unstimulated and untreated cells, *P < 0.05, **P < 0.01 and ***P < 0.001 compared with stimulated and
untreated cells.
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Figure 2 Quercetin inhibited the activation of c-Met in melanoma cells. (A) Cells were treated with the indicated concentrations of quercetin
for 6 h and then stimulated with or without HGF (100 ng/ml) for 10 min. Levels of c-Met and phospho-Met in total lysates were evaluated by
immunoblotting. The representative results (upper) and the relative phosphorylation levels (bottom) were shown. The relative levels of phospho-Met
were calculated after normalizing the levels of phospho-Met to total c-Met. (B) Cells were grown in serum-free medium overnight before
incubation with the indicated concentrations of quercetin for 6 h, after stimulation with or without 100 ng/ml HGF for 10 min, cells were lysed
for immunoblotting. The representative results (upper) and the relative phosphorylation levels (bottom) were shown. The relative levels of
phospho-Met were calculated after normalizing the levels of phospho-Met to the total c-Met. (C) Quercetin reduced c-Met homo-dimerization. Cells
were starved overnight and then treated with indicated concentrations of quercetin for 6 h. After that, these cells were stimulated with or without
HGF (100 ng/ml) for 10 min, and then incubated with BS3. Cell lysates were prepared for immunoblotting by using an anti-c-Met antibody. The arrows
indicated the dimer (D) and the monomer (M) c-Met. Molecular weights of the marker are shown on the left. The representative results (left) and the
relative expression levels of dimer c-Met (right) were shown. The relative levels of dimer c-Met were analyzed after normalizing the levels of dimer
c-Met to monomer c-Met. (D) Effect of quercetin on HGF mRNA expression. Cells were treated with indicated concentrations of quercetin for 24 h and
then the real-time PCR analysis was performed to detect the mRNA expression levels of HGF. Data were mean ± S.D. from three independent
experiments. *P < 0.05, **P < 0.01 and ##P < 0.01.
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HGF that induces sustained activation of its receptor c-
Met [30]. We wondered if quercetin affected the en-
dogenous HGF expression level. Real-time PCR data
showed that the mRNA expression levels of HGF inmelanoma A375 and A2058 cells were slightly reduced
after treating with quercetin for 24 h (Figure 2D).
Taken together, these findings suggest that quercetin
inhibits c-Met activation probably mainly by inhibiting
c-Met phosphorylation and dimerization.
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associated with reduced expression of fatty acid synthase
To verify the effect of quercetin on c-Met expression, we
performed the Western blot analysis in melanoma
MeWo and sk-mel-2 cells in addition to A375 and
A2058 cells. Whole-cell lysates from the four cells treated
with various concentrations of quercetin (0, 40, 60 and
80 μM) for 24 h, or a fixed concentration (60 μM) for
various durations (0, 3, 6 and 12 h) were immuno-blotted
with the c-Met antibody. We found that quercetin
reduced c-Met expression in both dose- and time-
dependent manners in these four cell lines (Figure 3A
and B). Since c-Met is a membrane receptor tyrosine kin-
ase, we examined if quercetin inhibited cell surface c-Met
expression. After treating A375 and A2058 cells with the
indicated concentrations of quercetin for 24 h, we isolated
the membrane and cytosolic fractions for Western blot
analyses. As shown in Figure 3C, the expression levels of
c-Met were dose-dependently reduced by quercetin in
both membrane and cytosolic fractions of the A375 and
A2058 cells.
It has been reported that palmitate whose synthesis re-
quires fatty acid synthase (FAS) involvement is essential
for maintaining c-Met expression, and inhibition of FAS
using inhibitors or the shRNA knockdown greatly re-
duces c-Met expression [31]. The activity of FAS is
tightly correlated with melanoma progression and me-
tastasis. Studies showed that malignant melanomas
expressed higher levels of FAS than nevi, and metastatic
melanomas expressed the highest levels of FAS [32].
Moreover, increased FAS expression was usually associ-
ated with melanoma invasion depth and poor patient
survival [32-34]. Quercetin has been reported to inhibit
FAS activity, which was associated with quercetin-
mediated prostate cancer cell apoptosis [35]. Quercetin
also reduced FAS expression levels and inhibited cell
proliferation in nasopharyngeal carcinoma cells [36].
Interestingly, in this study, quercetin not only down-
regulated c-Met expression levels, but also reduced FAS
expression in human melanoma A375, A2058, MeWo and
sk-mel-2 cells (Figure 3D). We suggested that quercetin-
afforded down-regulation of c-Met was probably caused
by inhibiting FAS. As expected, C75, a specific inhibitor of
FAS, inhibited c-Met with kinetics similar to that for inhi-
biting FAS (Figure 3E). More importantly, addition of
palmitate reduced quercetin-mediated c-Met reduction in
a dose-dependent manner (Figure 3F). These results sug-
gest that inhibition of FAS expression contributes to the
inhibitory effect of quercetin on c-Met expression.
Quercetin suppressed the activation of c-Met downstream
molecules
After phosphorylation, c-Met recruits adaptor protein
Gab1 (Grb2-associated binding protein 1), phosphorylatesGab1 at tyrosine site 307 and hence activates downstream
FAK (Focal Adhesion Kinase) and PAK (p21-activated kin-
ase). Activation of FAK and PAK pathways results in in-
creased cell motility, migration and invasion [9]. To
determine if quercetin inhibited the c-Met downstream
molecules, A375 and A2058 cells were treated with vari-
ous concentrations of quercetin for 24 h and the whole-
cell lysates were prepared for Western blot analyses. We
found that the levels of phosphorylated Gab1 at the tyro-
sine 307 (Tyr307) site in both A375 and A2058 cells were
reduced in a dose-dependent manner (Figure 4A), and the
activation of both FAK and PAK were inhibited by quer-
cetin treatment in a dose-dependent manner (Figure 4B
and C). To eliminate the influence of serum growth fac-
tors, cells were starved overnight and treated with either
the vehicle or quercetin (60 μM) in serum-free medium
for 6 h, followed by stimulation with HGF (100 ng/ml) for
10 min. Western blot analyses showed that under the
starved conditions, the phosphorylation of Gab1 was sig-
nificantly reduced in A2058 cells, while stimulation with
HGF resulted in a remarkable increase in Gab1 phosphor-
ylation which was completely abolished by quercetin pre-
treatment (Figure 4D, left). The activation of FAK and
PAK in A2058 cells were significantly inhibited by quer-
cetin under both HGF-stimulated and unstimulated
conditions (Figure 4D, middle and right). These data dem-
onstrate that quercetin suppresses the activation of c-Met
downstream molecules Gab1, FAK and PAK.
The inhibitory effect of quercetin on cell migration was
partially reversed by PAK or FAK overexpression
To better understand the involvement of c-Met signaling
in quercetin-mediated anti-metastatic effects, we investi-
gated whether overexpression of PAK or FAK reversed
the quercetin-mediated inhibitory effect on migration.
A2058 cells were transiently transfected with either a
FAK-expressing construct (or a PAK-expressing con-
struct) or an empty vector. After 24 h transfection, the
expression of FAK and phospho-FAK were increased re-
markably, and the quercetin-mediated FAK inhibition
was also partially reversed (Figure 5A and B). Similar re-
sults were observed in the PAK-expressing construct
transfected cells, overexpression of PAK reversed
quercetin-induced FAK inhibition (Figure 5A and B).
Furthermore, cells that transfected with PAK or FAK
constructs showed a slight but significant increase in the
migratory abilities as compared with cells that were
transfected with empty vector (#P < 0.05). Quercetin
treatment (40 μM) inhibited the cell migratory abilities.
This inhibitory effect was reduced from 48% to 33% in
PAK overexpressing cells, and from 48% to 30% in FAK
overexpressing cells. These data indicate that the inhibi-
tory effect of quercetin on migration is partially reduced
by the overexpression of PAK or FAK in melanoma cells.
Figure 3 (See legend on next page.)
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Figure 3 Quercetin reduced c-Met levels through the inhibition of FAS. A375, A2058, MeWo and sk-mel-2 cells were treated with (A) various
concentrations of quercetin for 24 h or (B) a fixed concentration (60 μM) for various durations, and then the whole-cell lysates were prepared
and the Western blot analysis was performed to determine the expression level of c-Met. (C) A375 and A2058 cells were treated with indicated
concentrations of quercetin for 24 h, and then the membrane and cytosolic lysates were prepared. The expression levels of c-Met in the two
fractions were examined by immunoblotting. (D) A375, A2058, MeWo and sk-mel-2 cells were treated with indicated concentrations of quercetin
for 24 h, and then the expression of FAS were determined by immunoblotting. (E) A375 and A2058 cells were treated with indicated concentrations
of C75 for 24 h and then the immunoblotting assay was conducted to determine the expression levels of FAS and c-Met. (F) A2058 cells were
exposed to either the vehicle or 60 μM quercetin for 24 h in the absence or presence of palmitate, and then the whole-cell lysates were
prepared for immunoblotting by using a c-Met antibody. Independent experiments were performed at least three times, and the results from a
representative experiment are shown. The relative expression levels were analyzed by Image J software and shown as mean ± S.D., *P < 0.05, **P < 0.01.
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The HGF/c-Met pathway is activated in various types of
cancer, which stimulates cancer cell growth and metasta-
sis [9]. HGF is a multifunctional cytokine acting as a
mitogen, motogen and morphogen [37]. Most cancers
express both HGF and c-Met, leading to autocrine acti-
vation of c-Met. Besides, aberrant c-Met activation can
also be achieved through c-Met overexpression, activat-
ing c-Met mutations, or c-Met gene amplification [38].
In melanoma, HGF and c-Met are expressed [9] and in-
volved in tumorigenesis [30]. In this study, we found
that quercetin, a widely existed dietary flavonoid, sup-
pressed c-Met signaling by inhibiting c-Met phosphoryl-
ation and dimerization (Figure 2A, B and C). Quercetin
also inhibited HGF-stimulated melanoma cell migration
and invasion (Figure 1), which was in agreement with
the previous studies that quercetin inhibited HGF-
stimulated migration and invasion in human medullo-
blastoma cell DAOY [27] and human hepatoma HepG2
cells [28]. In addition, many other known flavonoids,
such as EGCC [39], luteolin [28,31], kaempferol [27] and
myricetin [27] also showed inhibitory effects on HGF-
stimulated cancer cells migration. These observations in-
dicated that these plant-derived flavonoids shared similar
activities and may be useful in melanoma treatment and
prevention.
Since some melanoma cells were reported to express
HGF and secret a detectable level of HGF to induce con-
stitutive activation of c-Met [30], we wondered if quer-
cetin exerted its effects by affecting HGF autocrine. We
collected the culture medium of quercetin-treated A375
and A2058 cells, and examined the HGF levels by
ELISA, but the level of secreted HGF was too low to be
detected. Besides, we also found that the inhibitory effect
of quercetin on HGF mRNA expression was not obvious
(Figure 2D). Based on these results we could not draw a
conclusion regarding the impact of HGF autocrine on
quercetin-mediated c-Met signaling inhibition.
We found that c-Met protein levels were decreased
after quercetin treatment in both dose- and time-
dependent manners (Figure 3A and B). Since melanoma
can be divided into three mutually exclusive genetic sub-
sets: BRAF mutant melanoma, NRAS mutant melanomaand melanoma of wild type at both loci [40], to confirm
the generality of this finding, beside two BRAF mutant
melanoma cell lines A375 and A2058, NRAS mutant
melanoma cell line sk-mel-2 and wild type NRAS and
BRAF melanoma cell line MeWo with constant c-Met
activation [12] were also used. Results showed that
treatment with quercetin down-regulated the expres-
sion levels of c-Met in all these four cell lines (Figure 3A
and B), suggesting that the inhibitory effect of quercetin
on c-Met receptor is a general phenomenon in melan-
oma. It was further found that c-Met expression was
higher in membrane fractions than in cytosol fractions,
and c-Met in both fractions were inhibited by quercetin
treatment (Figure 3C). We also found that quercetin
did not affect the mRNA expression levels of c-Met in
all these cell lines (data not shown), which indicated
that quercetin post-transcriptionally down-regulated c-
Met expression. Coleman et al. identified a regulatory
link between FAS and c-Met. They found that inhib-
ition of FAS by using inhibitors (luteolin or C75) or the
shRNA knockdown approach can down-regulate c-Met
expression in human prostate cancer cells, and the pro-
duction of the 16-carbon fatty acid palmitate by FAS is
required for maintaining c-Met expression [31]. Similar
results have also been observed in diffuse large B cell
lymphoma by Uddin et al. [41] and in breast cancer by
Hung et al. [42]. Furthermore, Coleman et al. found
that all the flavonoids luteolin, apigenin, and quercetin,
which possess a same moiety with a C2-C3 double
bond in the C-ring, reduced c-Met expression in hu-
man prostate cancer cells [31]. In this study, we found
that quercetin reduced c-Met expression, C75, a spe-
cific inhibitor of FAS, showed similar inhibitory effect
on the expression of FAS and c-Met (Figure 3E), and ex-
ogenous palmitate prevented quercetin-induced reduction
of c-Met (Figure 3F), further supporting a role of FAS in
maintaining c-Met expression levels. However, the mech-
anism by which FAS inhibition decreases c-Met expres-
sion is not yet clear. A possible explanation is that FAS
inhibition may cause an imbalance in the membrane
phospholipids levels, which may result in decreased c-Met
membrane localization [41,43]. Lipid rafts are membrane
microdomains that serve as platforms for cell signaling,
Figure 4 (See legend on next page.)
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Figure 4 Quercetin suppressed the activation of c-Met downstream molecules. (A, B and C) A375 and A2058 cells were treated with indicated
concentrations of quercetin for 24 h. (D) A2058 cells were starved overnight and then exposed to the vehicle or quercetin (60 μM) for 6 h. After
that, these cells were stimulated with or without HGF (100 ng/ml) for 10 min. For each experiment, the whole-cell lysates were prepared and
probed by Western blot using specific antibodies. Independent experiments were performed at least three times, and the results from a
representative experiment are shown. The relative expression levels were analyzed by Image J software and shown as mean ± S.D., *P < 0.05, **P < 0.01.
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[44]. Recent studies found that altering the structure or
function of lipid rafts prevented the activation of c-Met
[45]. Quercetin is also reported to suppress lipid biosyn-
thesis in breast cancer MDA-MB-231 cells [35]. There-
fore, the quercetin-mediated reduction of c-Met in
melanoma cells may be due to FAS inhibition.
After phosphorylation on tyrosine site 1349, c-Met
becomes a docking site for recruiting Gab1, which fur-
ther activates downstream FAK and PAK [9]. Activa-
tion of both c-Met/Gab1/FAK and c-Met/Gab1/PAK
signalings promotes tumor metastasis [9]. Our data
showed that quercetin dose-dependently decreased the
levels of phospho-Gab1, phospho-FAK and phospho-PAK
(Figure 4A, B and C), suggesting that inhibition of the
c-Met/Gab1/FAK and c-Met/Gab1/PAK pathways mayFigure 5 Overexpression of PAK or FAK partially reversed the migration-inh
with a FAK-expressing construct, a PAK-expressing construct, or an empty v
transfected with FAK (or PAK)-expressing construct. (B) After transfection, c
on FAK (or PAK) overexpressed cells were determined by immunoblotting.
after treated with quercetin for 48 h. The relative quantitative determinations
The data shown here are the mean ± S.D. from three independent experimencontribute to the anti-metastatic effects of quercetin. It
is well-known that quercetin has multiple targets in-
cluding receptor tyrosine kinases, matrix metallopro-
teinase, mitochondria and other signaling enzymes [46].
Besides Gab1, c-Met can also activate other molecules
such as STAT3 [8] which is involved in melanoma me-
tastasis. STAT3 can be suppressed by quercetin treat-
ment as shown in our previous study [29]. Therefore,
we could not exclude the possibilities that quercetin in-
hibits melanoma metastasis by modulating other pathways
downstream of c-Met. Indeed, overexpression of FAK or
PAK only partially reversed quercetin-mediated inhibitory
effects on melanoma cell migration (Figure 5C). Whether
overexpression of both PAK and FAK can completely re-
verse the migration inhibitory effect of quercetin in mel-
anoma cells needs to be further studied.ibition effect of quercetin. A2058 cells were transiently transfected
ector for 24 h. (A) Expression levels of FAK (or PAK) on cells that
ells were treated with quercetin for 24 h, and the effects of quercetin
(C) Cell migratory abilities were measured by migration chamber assay
of migrated cells were calculated with 5 fields counted per experiment.
ts. #P < 0.05, *P < 0.05 and ** < 0.01.
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In summary, our previous [29] and current studies show
that quercetin suppresses melanoma cell migration and
invasion. This effect is, at least in part, due to the inhib-
ition of HGF/c-Met signaling. Our findings provide
novel insights into the anti-melanoma molecular mecha-
nisms of quercetin, and further suggest a potential role
of quercetin in melanoma management.
Methods
Reagents and antibodies
Antibodies against phospho-Met (Tyr1234/Y1235), phospho-
Met (Tyr1349), phospho-Met (Tyr1003), c-Met, phospho-
Gab1 (Tyr307), FAK, phospho-FAK (Tyr576/577),
phospho-FAK (Tyr925), phospho-FAK (Tyr397), PAK1/
2/3, phospho-PAK1 (Ser144)/PAK2 (Ser141), phospho-
PAK1 (Ser199/204)/PAK2 (Ser192/197), phospho-PAK1
(Thr423)/PAK2 (Thr402) and FAS were obtained from
Cell Signaling Technology (Beverly, MA, USA). Anti-
GAPDH was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Goat anti-rabbit IgG, goat anti-
mouse IgG and protein markers were supplied by Bio-
Rad (Hercules, CA, USA). Recombinant human HGF
was obtained from PeproTech (PeproTech, NJ, USA).
Other chemicals were obtained from Sigma–Aldrich
(St. Louis, MO, USA). Quercetin was obtained from
Chromadex (USA). The stock solution of 100 mM
quercetin was prepared in dimethyl sulfoxide (DMSO)
and stored at −20°C. Palmitate was complexed to bo-
vine serum albumin as previously described [47]. In
short, sodium palmitate was dissolved in ethanol:H2O
(1:1, v/v) at 70°C at a final concentration of 150 mM,
then the solutions were complexed with fatty-acid-free
BSA (10% solution in H2O) by stirring for 1 h at 37°C
and then diluted in culture medium. The final molar ra-
tio of fatty acid:BSA was 5:1.
Cell culture
A375, A2058, sk-mel-2 and MeWo cell lines were ob-
tained from the American Type Culture Collection
(ATCC, USA), and were incubated in high glucose
Dulbecco’s modified Eagle’s medium (DMEM, GIBCO,
USA), supplemented with 10% (v/v) fetal bovine serum
(FBS, GIBCO, USA) and 1% penicillin/streptomycin
(P/S, GIBCO, USA) at 37°C in a humidified atmos-
phere of 5% CO2.
Cell migration and invasion assay
The cell migratory ability was tested using a commercial
Transwell insert (8 μm pore size, Corning, NY, USA).
A2058 and A375 cells were suspended in serum-free
DMEM medium containing 0.1% BSA. Then 0.1 ml of
the cells suspension was added to the top of the Trans-
well inserts, and 0.5 ml of serum-containing mediumwith (+) or without (−) HGF (100 ng/ml) was plated in
the bottom wells. Quercetin was added to both inserts
and wells. The chambers were then assembled and incu-
bated for 24 h or 48 h at 37°C in a 5% CO2 incubator.
After that, non-invading cells were removed from the
upper surface of the membrane by scrubbing. The mi-
grated cells on the underside of the filter were first fixed
with 100% methanol and then stained by 0.1% crystal
violet solution and counted in five random fields. The
relative migration was calculated from the ratio of the
migrated cells that quercetin treated versus the vehicle
control cells.
For the invasion assay, BD BioCoat™Matrigel™ invasion
chamber (24 well plate, 8-μm pore size, BD Biosciences,
San Jose, CA, USA) were used. 0.5 ml warm (37°C)
serum-free medium was added to both the inserts and
the wells to allow the chamber rehydrated at 37°C in a
5% CO2 incubator for 2 h. Then A2058 and A375 cells
in 0.5 ml serum-free medium containing 0.1% BSA were
added to the inserts, while 0.75 ml of serum-containing
medium with or without HGF (100 ng/ml) was placed in
the lower chambers. Quercetin was added to both the
inserts and the lower chambers. Chambers were then as-
sembled and incubated for 24 h or 48 h at 37°C. Subse-
quent steps were performed in the same manner as
described for cell migration assay.
Western blot analysis
Membrane protein was extracted using Mem-PER™ Plus
kit (Thermo Scientific, Rockford, IL, USA) according to
the manufacturer’s protocol. Preparation of total protein
lysates and Western blot analysis were performed as
described previously [29]. Protein concentrations were
determined according to the Bio-Rad protein assay re-
agent. The cell lysates were separated on 6% or 8% gels
and transferred to nitrocellulose membranes. The mem-
branes were incubated in 5% skim milk in TBS-T buffer
at room temperature. Blocked membranes were incu-
bated with primary antibodies at 4°C overnight, followed
by incubation with secondary antibodies at room
temperature for 1 hour. After washing in TBS-T, immune-
reactive bands were visualized by chemiluminescence sub-
strate (Thermo Scientific, Rockford, IL, USA).
Real-time PCR
Total RNA was extracted with Trizol reagent (Invitrogen,
USA), and reverse-transcripted with oligo-dT using M-
MLV reverse transcriptase (Promega, USA) according to
the manufacturer’s protocol. Quantitative real time PCR
was carried out by monitoring the increase in fluorescence
of SYBR green with the ViiA 7 Real Time PCR System
(Applied Biosystems, USA). The primer sets were synthe-
sized by Invitrogen, HGF primers: forward TCCCCATCG
CCATCCCC and reverse CACCATGGCCTCGGCTGG,
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AGC and reverse CTTCACCACCTTCTTGATGTC.
Each sample was amplified in triplicate for quantification.
Data were analyzed by relative quantitation using the
ΔΔCt method and normalized to GAPDH.
Dimerization of c-Met
The dimerization of c-Met was analyzed as described
previously [48]. Melanoma cells were starved over-
night and then treated with vehicle control or quer-
cetin for 6 h, followed by stimulation with HGF
(100 ng/ml) on ice for 10 min. Subsequently, the cross-
linker Bis[sulfosuccinimidyl] substrate (BS3, 0.25 mM,
Thermo Scientific, Rockford, IL, USA) was added to cells
and reacted at 37°C for 5 min. Cells were then transferred
on ice for 10 min. After that, non-reactive BS3 were
quenched with 50 mM Tris–HCl (pH 7.4). Cell lysates
were separated by 6% SDS-PAGE and immunoblotted
with an anti-c-Met antibody.
Plasmid transient transfection
Plasmids pCMV6M-Pak1 (Addgene plasmid 12209) was
provided by Sells et al. [49] and myc-Rapr-FAK (Addgene
plasmid 25926) was supplied by Karginov et al. [50]. To
overexpress FAK and PAK, cells were transfected with
plasmids using Lipofectamine 2000 (Invitrogen, USA) ac-
cording to the manufacturer’s protocol. Empty pcDNA3.0
plasmid was used as mock transfectant. Cells were trans-
fected with plasmids for 24 h or 48 h before functional as-
says were carried out.
Statistical analysis
The Student’s t-test was used to analyze differences be-
tween two groups. All data were presented as means ±
S.D. from at least three independent experiments. P < 0.05
was considered as statistically significant.
Additional file
Additional file 1: Figure S1. Effect of quercetin on melanoma cell
proliferation. A375 and A2058 cells were treated with indicated concentrations
of quercetin for 24 h or 48 h. Cell viability was measured by the MTT assay.
Data were mean ± S.D. from three independent experiments.
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